<DOC>
	<DOCNO>NCT02094391</DOCNO>
	<brief_summary>Isolated limb perfusion ( ILP ) result good response rate locally advanced melanoma ( stage IIIB IIIC , AJCC 2009 ) . Outcome influence stage disease , reflect aggressiveness melanoma . Our objective demonstrate least double progression free survival patient adjuvant treatment Ipilimumab patient population unfavourable characteristic . PFS range 10-12 month . So least doubling period would clinically highly significant result .</brief_summary>
	<brief_title>Trial Ipilimumab After Isolated Limb Perfusion , Patients With Metastases Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients melanoma ITmetastases localize limb accessible surgical treatment associate regional node metastasis ( stage IIIB IIIC : TxN2c N3 ) ; 2 . Age 18 year , upper limit ; 3 . Evaluable disease accord RECIST 1.1 criterion ; 4 . ECOG performance status 01 ; 5 . Previous specific treatment ( chemotherapy , immunotherapy ) melanoma must stop inclusion wash period 3 week least ; 6 . Adequate hematologic , renal liver function define laboratory value perform within 46 week enrolment : White blood count ( WBC ) great equal 2.5x109/L Absolute neutrophil count ( ANC ) great equal 1x109/L Platelet count great equal 75x109/L Hemoglobin great equal 9 g/dL ( 5.6 mmol/L ) Serum creatinine less equal 2.5 time upper limit laboratory normal ( ULN ) ASAT ALAT &lt; 2 ULN Calcaemia &lt; 12 mg/dl ( 2.99 mmol/l ) 7 . Women childbearing potential must negative pregnancy test perform within seven day prior start study drug . Both men woman enrol trial must use adequate contraception treatment phase study 1 month afterwards ; 8 . Information patient signature inform consent . 1 . Surgical resectable tumor metastatic patient ( stage IV ) ; 2 . Significant cardiovascular disease , e.g congestive heart failure ( NYHA Class II , III IV ) , severe angina pectoris , cardiac arrhythmia control , myocardial infarction within 3 month period prior inclusion , venous thrombosis , occlusive peripheral arterial disease , recent pulmonary embolism ; 3 . Severe lymphoedema limb ; 4 . Patients contraindication limb hyperthermia ; 5 . Contraindication use vasopressin , anticoagulant , radioactive tracer monitoring ; 6 . Prior hypersensibility melphalan and/or tasonermin ; 7 . Prior treatment Ipilimumab anti PD1 PDL1 therapy ; 8 . Severe pulmonary dysfunction ; 9 . Recent history active peptic ulcer , severe ascites ; 10 . Simultaneous treatment cardiotoxic substance ( e.g anthracyclines ) ; 11 . Uncontrolled deep sepsis ; 12 . Pregnancy breastfeeding ; 13 . Person deprive right guardianship ; 14 . Impossibility submit medical followup trial geographical , social psychic reason ; 15 . History autoimmune disorder condition immunosuppression require current ongoing treatment systemic corticosteroid patient history significant symptomatic autoimmune disease ; 16 . Chronic steroid &gt; 10 mg/day chronic immunosuppressive treatment ; 17 . Uncontrolled infectious disease include positive testing HIV , HBV , HCV ; 18 . No second malignancy past 5 year exception surgically cure carcinoma insitu cervix basal squamous cell carcinoma skin . 19 . Patients blood supply extremity distal tumour suspect highly dependent tumour associate blood vessel . This clarified Doppler ultrasound .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>